Campath and renal transplant rejection

Philip G Thomas; Kanae Ishihara; Smita Vaidya; Kristene K Gugliuzza

doi:10.1111/j.1399-0012.2004.00288.x

Campath and renal transplant rejection

Clin Transplant. 2004 Dec;18(6):759-61. doi: 10.1111/j.1399-0012.2004.00288.x.

Authors

Philip G Thomas¹, Kanae Ishihara, Smita Vaidya, Kristene K Gugliuzza

Affiliation

¹ Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA. pgthomas@utmb.edu

PMID: 15516258
DOI: 10.1111/j.1399-0012.2004.00288.x

Abstract

No clear guidelines exist for the treatment of acute vascular rejection following renal transplantation. This report documents one patient who was treated with plasmapheresis, immunoglobulin and Campath with good initial response. However, rejection recurred resulting in graft loss and, in addition, the patient developed post-transplant lymphoma.

Publication types

Case Reports

MeSH terms

Adult
Alemtuzumab
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / therapeutic use*
Graft Rejection / drug therapy*
Graft Rejection / etiology
Humans
Kidney Transplantation / adverse effects*
Male

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Alemtuzumab